The shift in tuberculosis timing among people living with HIV in the course of antiretroviral therapy scale-up in Malawi.
Adult
Ambulatory Care Facilities
Anti-HIV Agents
/ adverse effects
Antitubercular Agents
/ therapeutic use
CD4 Lymphocyte Count
Cross-Sectional Studies
Female
HIV Infections
/ complications
Humans
Incidence
Malawi
/ epidemiology
Male
Middle Aged
Retrospective Studies
Time Factors
Tuberculosis
/ drug therapy
HIV
Antiretroviral therapy
Incidence
Malawi
Patients living with HIV
Tuberculosis
Journal
Journal of the International AIDS Society
ISSN: 1758-2652
Titre abrégé: J Int AIDS Soc
Pays: Switzerland
ID NLM: 101478566
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
received:
12
08
2018
accepted:
17
12
2018
entrez:
1
5
2019
pubmed:
1
5
2019
medline:
14
4
2020
Statut:
ppublish
Résumé
Although the use of antiretroviral therapy (ART) reduces HIV-associated tuberculosis (TB), patients living with HIV receiving ART remain at a higher risk of developing TB compared to those without HIV. We investigated the incidence of TB and the proportion of HIV-associated TB cases among patients living with HIV who are receiving ART. The study used TB registration and ART programme data collected between 2008 and 2017 from an integrated, public clinic in urban Lilongwe, Malawi. ART initiation was based on either WHO clinical staging or CD4 cell count. The CD4 thresholds for ART initiation eligibility was initially 250 cells/μL then changed to 350 cells/μL in 2011, 500 cells/μL in 2014 and to universal treatment upon diagnosis from 2016. Using TB registration data, we calculated the proportion of TB/HIV patients who were already on ART when they registered for TB treatment by year of TB registration. ART registration data were used to examine TB incidence by calendar year of ART follow-up and by time on ART. The overall proportion of TB/patients living with HIV who started TB treatment while on ART increased from 21% in 2008 to 81% in 2017 but numbers remained relatively constant at 500 TB cases annually. The overall incidence rate of TB among patients on ART was 1.35/100 person-years (95% CI 1.28 to 1.42). The incidence of TB by time on ART decreased from 6.4/100 person-years in the first three months of ART to 0.4/100 person-years after eight years on ART. TB incidence was highest in the first month on ART. The annual rate of TB among patients on ART rapidly decreased each calendar year and stabilized at 1% after 2013. Although the risk of developing TB decreased with year of ART initiation in univariable analysis, there was no significant association after adjusting for sex, age and reason for ART eligibility. The decline in TB incidence over calendar years suggests protective effects of early ART initiation. The high TB incidence within the first month of ART highlights the need for more sensitive tools such as X-ray and GeneXpert to identify patients living with HIV who have clinical and subclinical TB disease at ART initiation.
Identifiants
pubmed: 31038836
doi: 10.1002/jia2.25240
pmc: PMC6490056
doi:
Substances chimiques
Anti-HIV Agents
0
Antitubercular Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e25240Informations de copyright
© 2019 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.
Références
Lancet. 2018 Jul 28;392(10144):292-301
pubmed: 30032978
AIDS. 2007 Jul 11;21(11):1441-8
pubmed: 17589190
AIDS. 2009 Aug 24;23(13):1717-25
pubmed: 19461502
Crit Ultrasound J. 2012 Nov 21;4(1):21
pubmed: 23171481
Eur Respir J. 2015 Feb;45(2):547-9
pubmed: 25395030
AIDS. 2009 Mar 13;23(5):631-6
pubmed: 19525621
Trop Med Int Health. 2011 Nov;16(11):1397-403
pubmed: 21806742
AIDS. 2007 Mar 30;21(6):713-9
pubmed: 17413692
Lancet Infect Dis. 2010 Jul;10(7):489-98
pubmed: 20610331
J Int AIDS Soc. 2019 Apr;22(4):e25240
pubmed: 31038836
Lancet. 2011 May 7;377(9777):1588-98
pubmed: 21492926
Lancet Infect Dis. 2008 Aug;8(8):516-23
pubmed: 18652998
PLoS Med. 2012;9(7):e1001270
pubmed: 22911011
J Infect Dis. 2008 Jul 1;198(1):90-4
pubmed: 18498237
J Acquir Immune Defic Syndr. 2012 Aug 15;60 Suppl 3:S136-44
pubmed: 22797735
J Acquir Immune Defic Syndr. 2011 Aug 1;57(4):311-8
pubmed: 21423023
PLoS One. 2012;7(3):e34156
pubmed: 22479548
J Int AIDS Soc. 2017 Jun 23;20(1):21327
pubmed: 28691438
Lancet. 2014 Aug 23;384(9944):682-90
pubmed: 24835842